Literature DB >> 31302756

Answer to the letter to the editors by Matthes and colleagues regarding our systematic reviews on mistletoe.

Jutta Huebner1, M Freuding2, C Keinki2, O Micke3, J Buentzel4.   

Abstract

Mesh：

Year:  2019        PMID： 31302756     DOI： 10.1007/s00432-019-02979-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  5 in total

1.  Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review.

Authors:  Thomas Ostermann; Christa Raak; Arndt Büssing
Journal:  BMC Cancer       Date:  2009-12-18       Impact factor: 4.430

2.  Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial.

Authors:  Wilfried Tröger; Danijel Galun; Marcus Reif; Agnes Schumann; Nikola Stanković; Miroslav Milićević
Journal:  Dtsch Arztebl Int       Date:  2014-07-21       Impact factor: 5.594

Review 3.  Mistletoe therapy in oncology.

Authors:  M A Horneber; G Bueschel; R Huber; K Linde; M Rostock
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

4.  Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival.

Authors:  W Tröger; D Galun; M Reif; A Schumann; N Stanković; M Milićević
Journal:  Eur J Cancer       Date:  2013-07-24       Impact factor: 9.162

5.  A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients.

Authors:  Alessandra Longhi; Marcus Reif; Erminia Mariani; Stefano Ferrari
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-31       Impact factor: 2.629
  5 in total
  1 in total

1.  Statement to an Insufficient Systematic Review on Viscum album L. Therapy.

Authors:  Harald Matthes; Anja Thronicke; Ralf-Dieter Hofheinz; Erik Baars; David Martin; Roman Huber; Thomas Breitkreuz; Gil Bar-Sela; Daniel Galun; Friedemann Schad
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-18       Impact factor: 2.629
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.